Please login to the form below

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

J&J’s Erleada cleared for early prostate cancer in Europe

Xtandi is also approved for more advanced, metastasised CRPC, where it competes with J&J’s $4bn-plus androgen synthesis inhibitor Zytiga (abiraterone acetate), and reported $180m in alliance revenues in

Latest news

Generic threat looms to J&J’s blockbuster Zytiga in US

8, 822, 438) for Zytiga (abiraterone acetate) is invalid, and sought a preliminary injunction while that case is considered by the Court of Appeals for the Federal Circuit, which is expected
Daily Brief: NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

families. “We firmly believe that the clinical effectiveness demonstrated in the multinational, Phase 3 LATITUDE study, means that abiraterone plus ADT should be made available routinely to NHS patients that need
EMA starts review of Xtandi in non-metastatic prostate cancer

At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.
J&J’s Erleada first US drug for non-metastatic prostate cancer

momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the US, which accounted for around half of the drug’s $2.5bn in sales in
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... Pfizer’s chief operating officer Albert Bourla told analysts

More from news
Approximately 5 fully matching, plus 51 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

outperforming J&J's Zytiga [abiraterone].
Taking a strategic approach

But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
Pharma deals during October 2013

AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Interview: Cesar Rodriguez, Janssen

Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Senior Account Manager: Competitive Salary Offered

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Medical Writer: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Associate Director: £75, 000-90, 000

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Medical Writer: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager / Account Director: Competative

Account Director: Competitive Salary Offered

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Global Business Development Director – Health Education: excellent commission

Business Director: Competitive Salary Offered

Account Director, Medical Education: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Senior Account Manager: 35, 000-40, 000

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...